Last week a study showing that immunotherapies may lead to rapid tumor growth in a small subset of patients met with some concern among oncologists and researchers. They worried that the news could dampen enthusiasm surrounding cancer’s most promising new therapy.
Indeed, some of the researchers who observed the effect expressed hesitancy about sharing the news widely.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
We’re not God. But some stupid guys always try to act like God.